1. Home
  2. ARES vs RMD Comparison

ARES vs RMD Comparison

Compare ARES & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ares Management Corporation

ARES

Ares Management Corporation

HOLD

Current Price

$173.92

Market Cap

33.1B

Sector

Finance

ML Signal

HOLD

Logo ResMed Inc.

RMD

ResMed Inc.

HOLD

Current Price

$250.60

Market Cap

36.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARES
RMD
Founded
1997
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.1B
36.4B
IPO Year
2014
1995

Fundamental Metrics

Financial Performance
Metric
ARES
RMD
Price
$173.92
$250.60
Analyst Decision
Buy
Buy
Analyst Count
13
13
Target Price
$190.33
$292.27
AVG Volume (30 Days)
4.8M
893.0K
Earning Date
11-03-2025
01-29-2026
Dividend Yield
2.58%
0.95%
EPS Growth
9.11
29.59
EPS
2.38
9.77
Revenue
$5,355,558,000.00
$5,257,400,000.00
Revenue This Year
$16.40
$9.85
Revenue Next Year
$23.00
$7.32
P/E Ratio
$72.90
$25.82
Revenue Growth
45.54
9.36
52 Week Low
$110.63
$199.92
52 Week High
$200.49
$293.81

Technical Indicators

Market Signals
Indicator
ARES
RMD
Relative Strength Index (RSI) 71.87 48.59
Support Level $160.00 $245.97
Resistance Level $181.19 $259.99
Average True Range (ATR) 4.80 5.40
MACD 2.41 0.59
Stochastic Oscillator 80.53 62.13

Price Performance

Historical Comparison
ARES
RMD

About ARES Ares Management Corporation

Ares Management is one of the world's largest alternative-asset managers, with $595.7 billion in total assets under management, or AUM, including $367.6 billion in fee-earning AUM, at the end of September 2025. The company has four main business segments: private credit ($391.5 billion in total AUM and $240.2 billion in fee-earning AUM), private equity, ($25.1 billion/$11.8 billion), real estate/real assets ($132.4 billion/$80.5 billion), and other alternatives ($46.7 billion/$35.1 billion). The firm primarily serves institutional investors (80% of AUM) and high-net-worth individuals (20%). Ares operates through more than 35 offices in over 15 countries around the globe.

About RMD ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Share on Social Networks: